Available IHC assays may be suboptimal for detecting low levels of HER2 protein expression, "and could result in false-negative and false-positive test determinations around the IHC 0/IHC 1+ threshold that would incorrectly influence treatment recommendations and potentially impact data from ongoing clinical trials that still rely on them," noted authors of a guideline update on HER2 testing opens in a new tab or window in breast cancer from the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP).
For the full article click here: HER2 Low and Ultralow Designations Open Door to Expansion of ADCs in Breast Cancer